Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 430 participants.
Also called NCT07244003
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 430 participants
- Registry
-
NCT07244003
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07244003. Randomized; no masking; primary purpose treatment. Start 2025-03-29 (actual); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
- Acronym
- MESSAGE
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Triple Therapy of Other Oral Antidiabetic Drugs
- Intervention (Drug)
- ganagliflozin
- Intervention (Drug)
- liraglutide
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07244003- Content hash
94ad0c3eefed3a6a9ef6531d35b3367aec30bd600378edabb95b0d860561eece